Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development,dedicated server and commercialization of medicines for diabetes, obesity, and other diseases in the United States. The company also has research through web design and wireless internet development programs in the therapeutic areas of diabetes and obesity. It sells BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection for the treatment of patients with Type II diabetes. Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California.